HOSPITAL UNIVERSITARIO RUBER
Departamento
University of California, San Francisco
San Francisco, Estados UnidosPublicaciones en colaboración con investigadores/as de University of California, San Francisco (18)
2023
-
Holistic Treatment Response: An International Expert Panel Definition and Criteria for a New Paradigm in the Assessment of Clinical Outcomes of Spinal Cord Stimulation
Neuromodulation, Vol. 26, Núm. 5, pp. 1015-1022
-
Impact of Long-Term Evoked Compound Action Potential Controlled Closed-Loop Spinal Cord Stimulation on Sleep Quality in Patients With Chronic Pain: An EVOKE Randomized Controlled Trial Study Subanalysis
Neuromodulation, Vol. 26, Núm. 5, pp. 1030-1038
-
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
Breast Cancer Research, Vol. 25, Núm. 1
2022
-
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial
JAMA Oncology, Vol. 8, Núm. 7, pp. 1047-1052
2021
-
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581
2020
-
Oncological care organisation during COVID-19 outbreak
ESMO Open, Vol. 5, Núm. 4
-
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
Breast Cancer Research and Treatment, Vol. 184, Núm. 1, pp. 161-172
2019
-
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases
Future Oncology, Vol. 15, Núm. 19, pp. 2211-2225
2018
-
Change in topoisomerase 1–positive circulating tumor cells affects overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol
Clinical Cancer Research, Vol. 24, Núm. 14, pp. 3348-3357
2017
-
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (Breast Cancer Research and Treatment, (2017), 165, 2, (329-341), 10.1007/s10549-017-4304-7)
Breast Cancer Research and Treatment
-
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial
European Journal of Cancer, Vol. 76, pp. 205-215
-
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
Breast Cancer Research and Treatment, Vol. 165, Núm. 2, pp. 329-341
2016
2015
-
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): A randomised, open-label, multicentre, phase 3 trial
The Lancet Oncology, Vol. 16, Núm. 15, pp. 1556-1568
-
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Nature Genetics, Vol. 47, Núm. 3, pp. 250-256
2014
-
A Mouse Model Uncovers LKB1 as an UVB-Induced DNA Damage Sensor Mediating CDKN1A (p21
WAF1/CIP1
) Degradation
PLoS Genetics, Vol. 10, Núm. 10
-
The appropriate use of neurostimulation of the spinal cord and peripheral nervous system for the treatment of chronic pain and ischemic diseases: The neuromodulation appropriateness consensus committee
Neuromodulation, Vol. 17, Núm. 6, pp. 515-550
-
The appropriate use of neurostimulation: Avoidance and treatment of complications of neurostimulation therapies for the treatment of chronic pain
Neuromodulation, Vol. 17, Núm. 6, pp. 571-598